SCHEMBL18571838

SCHEMBL18571838

Nc1ncnc2c1c(F)cn2[C@@H]1O[C@H](COc2ccc3cccnc3c2)[C@@H](O)[C@H]1O

nearest known ligand 0.72

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ PRMT5 O14744 16/20 0.72
▸ WDR77 Q9BQA1 2/20 0.72
▸ METTL3 Q86U44 13/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18571842 0.90 METTL3 (0.83) PRMT5WDR77METTL3
SCHEMBL18572075 0.90 PRMT5 (0.81) PRMT5WDR77METTL3
SCHEMBL18572295 0.85 PRMT5 (0.59) PRMT5WDR77METTL3
SCHEMBL18572411 0.84 PRMT5 (1.00) PRMT5WDR77METTL3
SCHEMBL25015696 0.83 PRMT5 (1.00) PRMT5METTL3
SCHEMBL23892518 0.81 PRMT5 (0.51) PRMT5WDR77METTL3
SCHEMBL25016895 0.80 METTL3 (1.00) PRMT5METTL3
SCHEMBL25015913 0.80 PRMT5 (1.00) PRMT5METTL3
SCHEMBL18572077 0.79 PRMT5 (0.73) PRMT5WDR77METTL3
SCHEMBL18572184 0.79 PRMT5 (0.73) PRMT5WDR77METTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2023-10-19 — — US disclosed
EP-4219496-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2022-05-03 — — US disclosed
EP-3341368-B1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-06 — — EP disclosed
WO-2021079196-A2 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2021-04-29 — — WO disclosed
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-11-19 — — US disclosed
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2020-05-19 — — US disclosed
WO-2017032840-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11318157-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 106/4885METTL3 30/4885
US-20230027361-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 PRMT5 69/4885WDR77 98/4885METTL3 1/4885
US-20200360416-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 58/4885METTL3 31/4885
US-20230330127-A1 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 67/4885METTL3 69/4885
US-10653711-B2 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 106/4885METTL3 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback